Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

eneral for patients in moderate-to-severe acute pain where intravenous access is not readily available."

This study randomized 101 patients following bunionectomy surgery in a 2:2:1 ratio to 30 mcg sufentanil, 20 mcg sufentanil or placebo treatment arms.  The intent-to-treat (ITT) population in this study averaged 42.5 years of age with an average Body Mass Index of 28.2, and was evenly balanced for males and females (51%:49%) and ethnicity (54% Caucasian:46% non-Caucasian).  Ninety-one percent of patients entering the study completed the full 12-hour study period.  SPID-12 scores were +6.53 for 30 mcg sufentanil-treated patients and -7.12 for placebo-treated patients, the difference between the two groups being highly statistically significant (p=0.003).  The 20 mcg sufentanil-treated patients did not achieve SPID-12 scores that differentiated from placebo.

"The results from this study, funded by the U.S. Army Medical Research and Materiel Command, provide further validation of our sufentanil NanoTab product platform as an effective treatment for moderate-to-severe acute pain," said Richard King , president and CEO of AcelRx. "AcelRx will present these positive top-line data to USAMRMC, and intends to hold an End of Phase 2 meeting with the FDA to define the Phase 3 clinical program for ARX-04."

About ARX-04

ARX-04 is a product candidate in development for the treatment of moderate-to-severe acute pain, consisting of sufentanil, a high therapeutic index opioid, in AcelRx's proprietary NanoTab technology that enables rapid sublingual absorption when the NanoTab is placed under the tongue.  As a result, sufentanil NanoTabs are designed to provide rapid onset of analgesia in a non-invasive method of administration and display a consistent pharmacokinetic profile due to a high percentage of drug being absorbed sublingually instead of through the gastrointestinal tract.  We believe
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ... new report "Drug Delivery in Central Nervous ... to their offering. The delivery of ... challenge in the treatment of neurological disorders. Drugs ... administered systematically (e.g., by intravenous injection) for targeted ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets ( ... Processing Supplies and Equipment - Global Strategic Business Report" ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2014 through 2020. Also, a seven-year ...
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/z9s8mp/laboratory ... "Laboratory Centrifuges - Global Strategic Business Report" ... and forecasts are provided for the period 2014 ... provided for these markets. Market data and analytics ... profiles are primarily based on public domain information ...
Breaking Medicine Technology:Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2
... (NYSE: WPI ), a leading integrated global pharmaceutical ... third quarter 2011 financial results on Tuesday, November 1, 2011 ... Company will also host a conference call and webcast at ... its financial results and provide an update on the Company,s ...
... (Nasdaq: PRGO ; TASE) today announced that Perrigo ... meet with analysts on Tuesday, September 27, 2011 at 8:00 ... Square, New York, NY.   The day will ... businesses, finance, sales and marketing, quality, and research and development. ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 ZOOM+, ... of ZOOM+ Performance Health Insurance, announced today the opening ... Clean White 57 - a three-in-one complete dental exam, ... Clean Jr. for kids. Like all ZOOM+ services, ZOOM+Smile ... , “Why shouldn’t the dentist office be as inviting ...
(Date:6/2/2015)... June 02, 2015 Olive ... opening of Surrey’s first fertility clinic. Surrey ... a diverse, young community, with one of ... , Until now patients from Surrey ... to come into Vancouver or Burnaby for ...
(Date:6/2/2015)... 2015 TU-Automotive Detroit is the biggest ... 150+ speakers include senior execs from GM, Chrysler, Mercedes, ... provide a crucial status update on the automotive technology ... just 24 hours to secure one of the remaining ... wait for tomorrow. There are 70 sessions looking across ...
(Date:6/2/2015)... June 02, 2015 Vancouver, BC ... iData Research ( http://www.idataresearch.com ), the bone graft ... bone matrices (DBM) over traditional allograft materials. Because ... and thus an increase in operation time, alternative ... market growth in these synthetic materials is partly ...
(Date:6/2/2015)... National Autism Resource has partnered with ... development agency, to launch its new website and strategic ... new website is designed to help parents and ... autism. The site will expand its product line for ... from easy to understand information and helpful links to ...
Breaking Medicine News(10 mins):Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3
... Action Preserves Beneficiary Access to High Quality Nursing ... JOPLIN, Mo., Aug. 7 Citing the substantial,benefit ... to Protect Senior Care (CPSC) today thanked,Senator Susan ... effort,in Congress to stop the Bush Administration from ...
... Beneficiary Access to High Quality Nursing Home Care;,Helps ... Aug. 7 Citing the substantial,benefit in protecting ... Senior Care (CPSC) today thanked,Senator Elizabeth Dole for ... to stop the Bush Administration from moving forward ...
... 7 The dietary health of children is in,urgent ... only forward-thinking,convenient solutions with a line of fresh, healthy ... Most health guidelines recommend,children consume about 400 calories a ... the Public Interest, a consumer group based in Washington,D.C., ...
... Management, Inc. has a proven track record in supporting ... work with the U.S. Army,s Phase I/II clinical testing ... in Silver Spring, MD. CRM is the premier ... to expand its infectious disease capabilities, it looked to ...
... the next five ... Millennium Research Group, WALTHAM, Mass., Aug. 7 ... Health Imaging Systems 2008 report,the market for adjunct breast ... dedicated breast MRI systems, and,breast-specific gamma imaging (BSGI) systems ...
... with Toledo Children,s Hospital and Good Samaritan Hospital, ... NORTH HOLLYWOOD, Calif., Aug. 7 IPC ... leading national hospitalist,physician group practice company, announced today ... Children,s Hospital in Toledo,Ohio and Good Samaritan Hospital ...
Cached Medicine News:Health News:Senator Susan Collins Praised for Leading Successful Effort to Derail $4.3 Million Maine Medicare Cuts 2Health News:Senator Elizabeth Dole Praised for Leading Successful Effort to Derail $22.1 Million North Carolina Medicare Cuts 2Health News:Kidfresh Offers a Solution to the Rise of Unhealthy Eating Among Children With Fresh and Nutritious Prepared Meals for Kids 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 3Health News:Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013 2Health News:IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets 2
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Medicine Products: